Form 4: Sutro Biopharma Director Jon Marc Wigginton Granted 50,000 Stock Options

Sutro Biopharma, Inc. director Jon Marc Wigginton was granted 50,000 stock options with an exercise price of $0.85, vesting monthly over approximately one year.

Summary

• Jon Marc Wigginton, a Director of Sutro Biopharma, Inc. (STRO), was granted 50,000 stock options.
• The options have an exercise price of $0.85 per share.
• The transaction date for the grant was June 6, 2025.
• The options will vest at a rate of 8.33% of the total shares monthly, commencing July 6, 2025.
• Full vesting (100%) will occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026, contingent on Mr. Wigginton's continued service to the company.
• The options have an expiration date of June 6, 2035.
• Following this transaction, Mr. Wigginton beneficially owns 50,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, as the director's compensation is tied to the company's stock performance. It's a routine compensation event, not indicative of major operational changes, but generally viewed favorably as it incentivizes long-term value creation.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The long expiration date (June 6, 2035) provides a significant window for the director to benefit from long-term company growth.

Negatives

• The issuance of new stock options, if exercised, could lead to a slight dilution of existing shareholder equity.
• The exercise price of $0.85 is relatively low, which could be seen as a significant benefit to the director if the stock price is substantially higher than the current market price.

Risks

• The vesting of the options is subject to Jon Marc Wigginton's continued provision of service to Sutro Biopharma, Inc. on each vesting date.

Future Outlook

NA

Industry Context

The granting of stock options is a common form of executive and director compensation in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and align interests with shareholders. This practice is standard across publicly traded companies, particularly in growth-oriented sectors like biotech where future potential is a key driver of value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly prevalent in the biotech sector.
• While specific terms like exercise price and vesting schedules vary, the general mechanism is comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen, where equity-based incentives are a significant component of executive and board remuneration.
• The vesting schedule (monthly over approximately one year) is also a common approach to ensure continued service and performance alignment.

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, as it involves compensation from the company to an insider. This is a standard and disclosed form of related party dealing.

Stakeholder Impact

• Shareholders: Potential for slight dilution if options are exercised, but also increased alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Continued provision of service by Jon Marc Wigginton to ensure vesting of the stock options.
• Monitoring of Sutro Biopharma's stock performance, which will impact the value of the granted options.

Key Dates

Keywords

Sutro Biopharma, STRO, Jon Marc Wigginton, stock options, insider transaction, Form 4, beneficial ownership, director compensation, equity grant, vesting schedule